Synthesis of Novel Anticancer Agent Peloruside A

Back to all technologies
Download as PDF
65001
Peloruside A (1), a 16-membered macrolide antitumor agent, was first isolated by L. West and P. Northcote from the New Zealand marine sponge, Mycale hentscheli. It has shown potent antitumor activity against resistant cell lines, such as P388 murine leukemia cells with an IC50 value of 10 ng/mL. Peloruside A is a microtubule stabilizing agent operating with a similar mechanism to the most widely used anticancer agent, taxol, and has shown a synergistic effect with taxol itself.

Researchers at Purdue University have developed a process for synthetic production of Peloruside A, which is amenable to the development of analogs and derivatives of this important molecule. This synthetic strategy opens the possibility of creating unnatural analogs of Peloruside A with improved potency, bioavailability, and other pharmacokinetic properties. These developments will facilitate drug discovery for cancer treatment.

Advantages:
-Novel synthetic pathway to highly potent cancer drug
-Synthetic process amenable to drug discovery of improved therapeutics

Potential Applications:
-Medical/Healthcare
-Pharmaceuticals
-Drug Development
-Cancer Treatment
Jul 8, 2010
Utility Patent
United States
8,580,975
Nov 12, 2013

Jan 9, 2009
PCT-Patent
WO
(None)
(None)

Jan 9, 2009
NATL-Patent
European Patent
(None)
(None)

Jan 11, 2008
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org